ASSESSMENT OF SERIOUS ADVERSE REACTIONS AMONG PATIENTS ON TYROSINE KINASE INHIBITORS- IDENTIFICATION OF SIGNIFICANT SIGNALS FOR GASTROINTESTINAL HEMORRHAGE AND PULMONARY REACTIONS
Author(s)
Raisch DW1, Chen C1, Arabyat R1, Rafi JA1, Bennett CL2
1University of New Mexico College of Pharmacy, Albuquerque, NM, USA, 2University of South Carolina College of Pharmacy, Columbia, SC, USA
OBJECTIVES: Tyrosine kinase inhibitors (TKIs) provide target-specific therapies for certain types of malignancies. TKIs may be associated with serious adverse drug reactions. We searched the Food and Drug Administration’s Adverse Event Reporting System (FAERS) to identify specific adverse drug reactions associated with small molecule TKIs in the post-marketing setting. METHODS: The TKIs included were gefitinib, imatinib, lapatinib, nilotinib, erlotinib, pazopanib, sorafenib, and vandetanib. The adverse reactions evaluated were interstitial lung disease (ILD), pneumonitis, pleural effusion, and gastrointestinal hemorrhage, depression, and suicide. We searched FAERS for each TKI from their respective approval date and calculated empiric Bayesian geometric means (EBGM) to identify significant disproportionality signals of each drug and reaction. RESULTS: EBGM for ILD, pneumonitis, and pleural effusion were significant for gefitinib, imatinib, erlotinib, and sorafenib. EBGM for pleural effusion was also significant for nilotinib. The strongest EBGM signals were associated with gefitinib/ILD (25.4, n=320), gefitinib/pneumonitis (10.5, n=54), erlotinib/ILD (7.5, n=212), nilotinib/pleural effusion (7.0, n=101), erlotinib/pleural effusion (6.9, n=325), sorafenib/pleural effusion (6.4, n=70), imatinib/pleural effusion (6.3, n=413), gefitinib/pleural effusion (5.8, n=118), and erlotinib/pneumonitis (5.7, n=63). EBGM for gastrointestinal bleeding was significant for erlotinib (2.5, n=156) and sorafenib (4.3, n=63). No significant signals were found for depression or suicide with any of the TKIs. Mortality rates for the adverse reactions with significant signals were: ILD=50.8%, gastrointestinal bleeding=40.6%, pneumonitis=37.0%, and pleural effusion=31.5%. CONCLUSIONS: Serious pulmonary adverse reactions, with high rates of mortality, have been reported disproportionately more frequently with gefitinib, imatinib, erlotinib, nilotinib, and sorafenib. Gastrointestinal hemorrhage has been reported to FAERS disproportionately more often with erlotinib and sorafenib. Limitations of FAERS are that lack of signals among other TKIs may be due to less frequent use or reporting of these reactions to FAERS, or shorter post-marketing time periods. Physicians and pharmacists should inform and monitor patients on TKIs for these reactions.
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PCN4
Topic
Epidemiology & Public Health
Topic Subcategory
Safety & Pharmacoepidemiology
Disease
Oncology